https://www.selleckchem.com/pr....oducts/bms-986365.ht
Immune checkpoint inhibitors (ICIs) treatment is a breakthrough in managing metastatic solid tumours, but its use is associated with a high financial burden for public health care systems. Validated tools such as the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) are frameworks that might help to better assess the clinical benefit of these novel innovative cancer drugs. Here, we systematically analysed the number of European Medicines Agency-approved ICIs labels with an ESMO-MCBS grade 4 and
Like
Comment
Share
